Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma
Cancers · 02.03.2023 · 15 (5) · 1558
DOI: 10.3390/cancers15051558 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 02.03.2023. Verfasst von Borja Puertas und 18 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Investigación Biomédica de Salamanca (IBSAL), Cancer Research Center-IBMCC (USAL-CSIC), CIBERONC, University Hospital of Salamanca, 3700…. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
(1)
Background
New therapeutic strategies have improved the prognosis of multiple myeloma (MM), changing the accepted view of this disease from being incurable to treatable. (2)
Methods
We studied 1001 patients with MM between 1980 and 2020, grouping patients into ten-year periods by diagnosis 1980–1990, 1991–2000, 2001–2010 and 2011–2020. (3)
Results
After 65.1 months of follow-up, the median OS of the cohort was 60.3 months, and OS increased significantly over time: 22.4 months in 1980–1990, 37.4 months in 1991–2000, 61.8 months in 2001–2010 and 103.6 months in 2011–2020 (p < 0.001). Using novel agents in the front-line setting for myeloma patients yielded a significantly better OS than in those treated with conventional therapies, especially when combinations of at least two novel agents were used. The median OS of patients treated with the combination of at least two novel agents in induction was significantly prolonged compared to those treated with a single novel agent or conventional therapy in induction: 143.3 vs. 61.0 vs. 42.2 months (p < 0.001). The improvement was apparent in all patients regardless of age at diagnosis. In addition, 132 (13.2%) patients were long-term survivors (median OS ≥ 10 years). Some independent clinical predictors of long-term survival were identified: ECOG < 1, age at diagnosis ≤ 65 years, non-IgA subtype, ISS-1 and standard-risk cytogenetic. Achieving CR and undergoing ASCT were positively associated with >10 years of survival. (4)
Conclusions
The combination of novel agents appears to be the main factor for the improvement in survival in MM, which is becoming a chronic and even curable disease in a subtype of patients without high-risk features.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Instituto de Investigación Biomédica de Salamanca (IBSAL), Cancer Research Center-IBMCC (USAL-CSIC), CIBERONC, University Hospital of Salamanca, 37007 Salamanca, Spain.
- Department of Hematology, University Hospital Dr. José Molina Orosa (Lanzarote, Canary Islands), 35500 Las Palmas, Spain.
- Department of Hematology, University Hospital of León, 24071 León, Spain.
- Department of Hematology, University Hospital of Segovia, 40002 Segovia, Spain.
- Department of Hematology, University Hospital of Ávila, 05004 Ávila, Spain.
- Department of Hematology, University Hospital of Burgos, 09006 Burgos, Spain.
ORCID-Profile: Verónica González-Calle, Eduardo Sobejano-Fuertes, Abelardo Bárez, Jorge Labrador, Carlos Aguilar-Franco, Elena Alejo-Alonso, Ramón García-Sanz, Norma C Gutiérrez, María-Victoria Mateos
Zitieren
APA
Puertas, B., González-Calle, V., Sobejano-Fuertes, E., Escalante, F., Queizán, J. A., Bárez, A., Labrador, J., Alonso-Alonso, J. M., García de Coca, A., Cantalapiedra, A., Villaescusa, T., Aguilar-Franco, C., Alejo-Alonso, E., Rey-Bua, B., López-Corral, L., García-Sanz, R., Puig, N., Gutiérrez, N. C., & Mateos, M. V. (2023). Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma. Cancers, 15(5), 1558. https://doi.org/10.3390/cancers15051558
Vancouver
Puertas B, González-Calle V, Sobejano-Fuertes E, Escalante F, Queizán JA, Bárez A, et al. Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma. Cancers. 2023;15(5):1558. doi:10.3390/cancers15051558
BibTeX
@article{Puertas2023,
author = {Puertas, Borja and González-Calle, Verónica and Sobejano-Fuertes, Eduardo and Escalante, Fernando and Queizán, José A and Bárez, Abelardo and Labrador, Jorge and Alonso-Alonso, José María and García de Coca, Alfonso and Cantalapiedra, Alberto and Villaescusa, Teresa and Aguilar-Franco, Carlos and Alejo-Alonso, Elena and Rey-Bua, Beatriz and López-Corral, Lucía and García-Sanz, Ramón and Puig, Noemi and Gutiérrez, Norma C and Mateos, María-Victoria},
title = {Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma},
journal = {Cancers},
year = {2023},
volume = {15},
number = {5},
pages = {1558},
doi = {10.3390/cancers15051558}
}
EUVIMED